{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:59Z","timestamp":1761101099384},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/bmt.2012.214","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T14:33:50Z","timestamp":1352126030000},"page":"678-683","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure"],"prefix":"10.1038","volume":"48","author":[{"given":"S-H","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-A","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-H","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-E","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B-S","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-S","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-K","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-G","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-W","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-S","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-W","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"issue":"Suppl","key":"BFbmt2012214_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/107327480801504s03","volume":"15","author":"GJ Mufti","year":"2008","unstructured":"Mufti GJ, Chen TL . Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008; 15 (Suppl): 14\u201328.","journal-title":"Cancer Control"},{"key":"BFbmt2012214_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.leukres.2010.05.023","volume":"34","author":"M Mittelman","year":"2010","unstructured":"Mittelman M, Oster HS, Hoffman M, Neumann D . The lower risk MDS patient at risk of rapid progression. Leuk Res 2010; 34: 1551\u20131555.","journal-title":"Leuk Res"},{"key":"BFbmt2012214_CR3","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"LR Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895\u20133903.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012214_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223\u2013232.","journal-title":"Lancet Oncol"},{"key":"BFbmt2012214_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403\u2013411.","journal-title":"Blood"},{"key":"BFbmt2012214_CR6","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012214_CR7","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Garcia-Manero G, Batty N, Shan J, O\u2019Brien S, Cortes J et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116: 3830\u20133834.","journal-title":"Cancer"},{"key":"BFbmt2012214_CR8","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322\u20133327.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012214_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cncr.25598","volume":"117","author":"C Bello","year":"2011","unstructured":"Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011; 117: 1463\u20131469.","journal-title":"Cancer"},{"key":"BFbmt2012214_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1365-2141.2012.09076.x","volume":"157","author":"T Prebet","year":"2012","unstructured":"Prebet T, Gore SD, Thepot S, Esterni B, Quesnel B, Beyne Rauzy O et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012; 157: 764\u2013766.","journal-title":"Br J Haematol"},{"key":"BFbmt2012214_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2011.01697.x","volume":"87","author":"SE Lee","year":"2011","unstructured":"Lee SE, Kim YJ, Yahng SA, Cho BS, Eom KS, Lee S et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol 2011; 87: 510\u2013520.","journal-title":"Eur J Haematol"},{"key":"BFbmt2012214_CR12","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","volume":"105","author":"S Lee","year":"2005","unstructured":"Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449\u20133457.","journal-title":"Blood"},{"key":"BFbmt2012214_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.bbmt.2009.02.010","volume":"15","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704\u2013717.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012214_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937\u2013951.","journal-title":"Blood"},{"key":"BFbmt2012214_CR15","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079\u20132088.","journal-title":"Blood"},{"key":"BFbmt2012214_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419\u2013425.","journal-title":"Blood"},{"key":"BFbmt2012214_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.6004\/jnccn.2011.0027","volume":"9","author":"MR O\u2019Donnell","year":"2011","unstructured":"O\u2019Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011; 9: 280\u2013317.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFbmt2012214_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649\u2013655.","journal-title":"Am J Clin Oncol"},{"key":"BFbmt2012214_CR19","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2012214_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/annonc\/mdp258","volume":"21","author":"WR Sperr","year":"2010","unstructured":"Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010; 21: 114\u2013119.","journal-title":"Ann Oncol"},{"key":"BFbmt2012214_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012214_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","volume":"18","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012; 18: 1415\u20131421.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012214_CR23","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878\u20131887.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012214_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","volume":"113","author":"T Qin","year":"2009","unstructured":"Qin T, Jelinek J, Si J, Shu J, Issa JP . Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659\u2013667.","journal-title":"Blood"},{"key":"BFbmt2012214_CR25","first-page":"937","volume":"10","author":"AF List","year":"1996","unstructured":"List AF . Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10: 937\u2013942.","journal-title":"Leukemia"},{"key":"BFbmt2012214_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1053\/j.seminoncol.2011.04.012","volume":"38","author":"S Parmar","year":"2011","unstructured":"Parmar S, de Lima M, Deeg HJ, Champlin R . Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 2011; 38: 693\u2013704.","journal-title":"Semin Oncol"},{"key":"BFbmt2012214_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.seminoncol.2011.07.001","volume":"38","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G . Treatment of higher-risk myelodysplastic syndrome. Semin Oncol 2011; 38: 673\u2013681.","journal-title":"Semin Oncol"},{"key":"BFbmt2012214_CR28","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2009.26.3509","volume":"28","author":"S Faderl","year":"2010","unstructured":"Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010; 28: 2755\u20132760.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012214_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","volume":"28","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 2010; 28: 285\u2013291.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2012214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012214","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:13:14Z","timestamp":1648048394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2012214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFbmt2012214"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.214","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,5]]},"assertion":[{"value":"23 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Yoo-Jin Kim has received honoraria and clinical research support from the Jassen, Celgene and Sanofi Cooperation. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}